Oramed Pharmaceuticals Inc. (ORMP): who owns it and who trades it
As of Nov 16, 2026, ORMP insiders reported 4 open-market sales worth $1.2M and no purchases in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joshua Hexter (COO & CBO), with $746K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Oramed Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ORMP
85 funds and institutions reported ORMP shares worth $81.1M at the end of Q2 2026, about 42% of the company. The largest holder is Mercer Global Advisors Inc with 9.4%.
Funds and institutions (13F) 42%Everyone else 58%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Mercer Global Advisors Inc | 3.81M | 9.42% | $18.3M | +99% |
| Aquamarine Financial (Cayman) Ltd | 2.51M | 6.21% | $12.1M | +19% |
| Gem Investment Advisors, LLC | 2.00M | 4.94% | $9.6M | +22% |
| BlackRock, Inc. | 1.61M | 3.98% | $7.7M | +1644% |
| Murchinson Ltd. | 1.29M | 3.19% | $6.2M | -2% |
| BML Capital Management, LLC | 866,269 | 2.14% | $4.2M | -73% |
| Boothbay Fund Management, LLC | 578,638 | 1.43% | $2.8M | -4% |
| Geode Capital Management, LLC | 500,690 | 1.24% | $2.4M | +1962% |
| Goldman Sachs Group Inc | 253,293 | 0.63% | $1.2M | New |
| State Street Corp | 242,100 | 0.60% | $1.2M | New |
| Rathbones Group PLC | 233,018 | 0.58% | $1.1M | No change |
| Vanguard Portfolio Management LLC | 229,882 | 0.57% | $1.1M | New |
| Dimensional Fund Advisors LP | 202,609 | 0.50% | $974K | +28% |
| Northern Trust Corp | 184,920 | 0.46% | $889K | New |
| Renaissance Technologies LLC | 183,800 | 0.45% | $884K | +24% |
| Wells Fargo & Company | 166,000 | 0.41% | $798K | +5% |
| Bank of America Corp | 150,694 | 0.37% | $725K | +3% |
| Strs Ohio | 133,800 | 0.33% | $644K | New |
| Jane Street Group, LLC | 113,349 | 0.28% | $545K | +116% |
| O'shaughnessy Asset Management, LLC | 102,962 | 0.25% | $495K | -12% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ORMP insiders reported $0 of open-market purchases and $1.2M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Avraham Gabay | CFO | Sale plan | 20,000 | $4.51 | $90.2K | Form 4 |
| Oct 1, 2026 | Joshua Hexter | COO & CBO | Sale plan | 30,000 | $4.51 | $135K | Form 4 |
| Jul 1, 2026 | Joshua Hexter | COO & CBO | Sale | 137,000 | $4.46 | $611K | Form 4 |
| Jul 1, 2026 | Avraham Gabay | CFO | Sale | 73,360 | $4.51 | $331K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Joshua Hexter | COO & CBO | – | $746K | Oct 1, 2026 |
| Avraham Gabay | Chief Financial Officer | – | $421K | Oct 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ORMP short interest
Low short interest. 3.2% of ORMP shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went up 111%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.34M ORMP shares were sold short, 3.2% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 118,509 shares, buying them all back would take about 11.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.34M | 3.23% | -7% | 118,509 | 11.3 |
| Oct 15, 2026 | 1.45M | 3.49% | +1% | 139,567 | 10.4 |
| Sep 30, 2026 | 1.43M | 3.45% | +10% | 195,596 | 7.3 |
| Sep 15, 2026 | 1.31M | 3.14% | +13% | 175,933 | 7.4 |
| Aug 31, 2026 | 1.15M | 2.77% | +13% | 269,352 | 4.3 |
| Aug 14, 2026 | 1.03M | 2.47% | +23% | 175,277 | 5.8 |
| Jul 31, 2026 | 835,493 | 2.07% | +9% | 146,714 | 5.7 |
| Jul 15, 2026 | 765,356 | 1.89% | -13% | 306,923 | 2.5 |
| Jun 30, 2026 | 877,849 | 2.17% | +54% | 738,846 | 1.2 |
| Jun 15, 2026 | 570,447 | 1.41% | -13% | 187,604 | 3.0 |
| May 29, 2026 | 659,464 | 1.63% | +4% | 213,820 | 3.1 |
| May 15, 2026 | 635,431 | 1.57% | -2% | 186,020 | 3.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ORMP
Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 1 sale of ORMP. The latest was a sale by Brad Knott on Jan 10, 2025, reported Feb 25, 2025.
Purchases 0Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Jan 10, 2025 | Brad Knott (R-NC) | Sale | $15K–$50K | Self | Feb 25, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Oramed Pharmaceuticals company events
Oramed Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 17, 2026.
- Sep 17, 2026VoteReported shareholder vote results. Filing
- Jun 30, 2026AnnouncementThe Company and Scilex Holding Company agreed to a further extension of the outstanding payment obligations, including the outstanding principal amount, any accrued interest thereon and any other fees, owed by Scilex to the Company pursuant to (i) the Senior Secured Promissory Note dated September… Filing
- Mar 31, 2026DealThe information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly… Filing
- Feb 20, 2026AgreementOramed Pharmaceuticals Inc. entered into a Warrant Agreement with Scilex Holding Company. Filing
- Jan 14, 2026AgreementOramed Pharmaceuticals Inc. entered into that certain Share Purchase Agreement, by and among the Company, Lifeward Ltd. and Oratech Pharma, Inc., the Company’s wholly-owned subsidiary. Filing
- Jan 7, 2026AnnouncementOramed Pharmaceuticals Inc. issued a press release announcing it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. Filing
- Dec 31, 2025LeadershipThe board of directors of Oramed Pharmaceuticals Inc. received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Filing
- Dec 31, 2025AnnouncementAs previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. entered into an Option Agreement for the Repurchase of Warrants with Scilex Holding Company pursuant to which, among other… Filing
- Nov 17, 2025ResultsReleased financial results. Filing
- Nov 17, 2025AgreementThe Board of Directors of Oramed Pharmaceuticals Inc. declared a dividend of one common stock purchase right (a “Right”) for each outstanding share of common stock, par value $0.012 per share, of the Company. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Oramed Pharmaceuticals financials
Famous investors that hold ORMP
2 of the 50 well-known investors we track reported holding ORMP in their latest 13F filing. The largest position is Jim Simons's, worth $1.4M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 294,268 | $1.4M | 0.0% | +60% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 59,844 | $279K | 0.0% | +44% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ORMP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Aquamarine Financial (Cayman) Ltd | 13G/A | 6.4% |
| Nov 13, 2026 | Aquamarine Financial (Cayman) Ltd | 13G/A | 6.4% |
Questions about Oramed Pharmaceuticals Inc. (ORMP) stock
Who owns the most ORMP stock?
The largest reported owner of Oramed Pharmaceuticals Inc. (ORMP) is Mercer Global Advisors Inc, with 9.4% of the company. In total, 85 funds and institutions reported holding ORMP at the end of Q2 2026, together about 42% of the shares. See the largest owners.
Are ORMP insiders buying or selling?
In the last 12 months, ORMP insiders reported no open-market purchases and 4 sales worth $1.2M. The latest trade was on Oct 1, 2026. See every trade.
What is the short interest in ORMP?
As of Oct 30, 2026, 1.34M ORMP shares were sold short, 3.2% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 118,509 shares, buying them all back would take about 11.3 trading days (days to cover). See the history.
Have members of Congress traded ORMP?
Yes. 1 member of Congress reported 0 purchases and 1 sale of ORMP since Nov 17, 2024. The latest was reported on Feb 25, 2025. See the trades.
Which famous investors hold ORMP?
2 of the 50 well-known investors we track reported ORMP in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $1.4M. See all holders.
Executive pay
Oramed Pharmaceuticals's chief executive was paid a total of $4.8M for the year ended Dec 31, 2025, up 128% from $2.1M the year before. In the last 12 months, Oramed Pharmaceuticals's executives and directors bought no stock on the open market and sold $1.2M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.